{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T16:18:45Z","timestamp":1774541925381,"version":"3.50.1"},"reference-count":21,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2022,10,21]],"date-time":"2022-10-21T00:00:00Z","timestamp":1666310400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100001505","name":"Health Research Council of New Zealand","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001505","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2023,3]]},"abstract":"<jats:sec><jats:title>Aim<\/jats:title><jats:p>The aim of this work is to assess the safety and efficacy of two oral zoledronate preparations by determining their effects on bone resorption in healthy postmenopausal women.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The preparations studied were zoledronic acid in enteric\u2010coated capsules or a microparticle preparation of zoledronic acid in these capsules. Bone resorption was measured as \u03b2\u2010C\u2010telopeptideof type I collagen (CTX) in fasting serum. Separate cohorts, each of five women, were recruited and allocated in sequence to single doses of 20 mg, 40 mg, or 60 mg of oral zoledronate.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Zoledronate 20\u2009mg enteric capsules were well tolerated, reduced serum CTX by a median 51% at 1\u2009week, but by only 17% at 1\u2009month. Doses of 40 or 60\u2009mg of this preparation produced APR and\/or gastrointestinal symptoms in more than half of participants. With these doses, median CTX reduction at 1\u2009week was &gt;80%, ~70% at 1\u2009month, but only ~30% at 6\u2009months. Enteric capsules containing microparticles of zoledronate 20\u2009mg reduced CTX by a median 53% at 1\u2009week, with offset over 3\u2009months. Two or three of these capsules dosed weekly reduced CTX by ~50% at 1\u2009month, and by ~30% at 3 and 6\u2009months.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Oral zoledronate 20\u2009mg circumvents the problem of APR symptoms but, even with multiple doses, the anti\u2010resorptive effect is smaller and less sustained than with intravenous zoledronate. Probably a viable oral regimen of zoledronate dosing at intervals of weeks to months could be developed, but the advantage of infrequent dosing would be lost.<\/jats:p><\/jats:sec>","DOI":"10.1111\/bcp.15559","type":"journal-article","created":{"date-parts":[[2022,10,10]],"date-time":"2022-10-10T11:43:10Z","timestamp":1665402190000},"page":"1099-1104","source":"Crossref","is-referenced-by-count":6,"title":["Effect of oral zoledronate administration on bone turnover in older women"],"prefix":"10.1111","volume":"89","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6021-5458","authenticated-orcid":false,"given":"Ian R.","family":"Reid","sequence":"first","affiliation":[{"name":"Department of Medicine, Faculty of Medical and Health Sciences University of Auckland  Auckland New Zealand"},{"name":"Auckland District Health Board  Auckland New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingyuan","family":"Wen","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Faculty of Medical and Health Sciences University of Auckland  Auckland New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Mellar","sequence":"additional","affiliation":[{"name":"Department of Medicine, Faculty of Medical and Health Sciences University of Auckland  Auckland New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengyang","family":"Liu","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Faculty of Medical and Health Sciences University of Auckland  Auckland New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amani","family":"Jabr","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Faculty of Medical and Health Sciences University of Auckland  Auckland New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne M.","family":"Horne","sequence":"additional","affiliation":[{"name":"Department of Medicine, Faculty of Medical and Health Sciences University of Auckland  Auckland New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2022,10,21]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.2165\/11585470\u2010000000000\u201000000"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa067312"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa074941"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1808082"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2012.03.016"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012\u20102868"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2010\u20100597"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2012.10.028"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535\u20107163.TARG\u201009\u2010B57"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-17-0585"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.2174\/15672018113109990043"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.9734\/BJPR\/2016\/22044"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00198\u2010015\u20103145\u20107"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011807"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.161207"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365\u20102141.2008.07435.x"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2012.02.006"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.1797"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.4434"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/8756\u20103282(96)00182\u20102"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2005.05.003"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.15559","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bcp.15559","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.15559","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T11:35:52Z","timestamp":1692272152000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/bcp.15559"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,21]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["10.1111\/bcp.15559"],"URL":"https:\/\/doi.org\/10.1111\/bcp.15559","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,21]]}}}